The Gut Microbiome in Obesity and New FDA Approvals
โSome exciting news in the obesity pharmacotherapy space has occurred, opening up new therapeutic options for an area of metabolic medicine where there remains a great need,โ Robert H. Eckel, MD said, referring to last weekโs decision by the FDA to approve the obesity drug extended release naltrexone/bupropion (Contrave) and the recommendation by an FDA […]
